The French manufacturer of a temporary artificial heart for patients with severe heart failure, Carmat, announced on Monday in payments and requested the opening of a judicial administration procedure.
The company, which had alerted ten days
Waiting for the Court’s decision, “expected in the next few days,” Carmat requested the suspension of his stock market “from Monday, June 30, 2025”, before the opening of the markets.
Created in 2008, the company had explained that it had to gather at least 3.5 million euros for June 30, as well as about 20 million euros by the end of the year. He had launched a donation campaign to guarantee the search for his activities.
The opening of a judicial administration procedure, according to her, would constitute “the most appropriate framework to facilitate this prosecution.”
Carmat says that “whatever the decision of the Court”, “will strive to continue guaranteeing the support of patients who currently benefit from the artificial heart Aeson.”
Carmat’s artificial heart is intended for patients with terminal heart failure waiting for the transplant. To date, 122 patients have been treated with AESON.
The company had voluntarily suspended the locations between the late 2021 and October 2022 to provide improvements to the device after dysfunctions that had cost two patients.
Source: BFM TV
